NO883263L - Fremgangsmaate for fremstilling av terapeutisk aktive benzimidazol-derivater. - Google Patents
Fremgangsmaate for fremstilling av terapeutisk aktive benzimidazol-derivater.Info
- Publication number
- NO883263L NO883263L NO88883263A NO883263A NO883263L NO 883263 L NO883263 L NO 883263L NO 88883263 A NO88883263 A NO 88883263A NO 883263 A NO883263 A NO 883263A NO 883263 L NO883263 L NO 883263L
- Authority
- NO
- Norway
- Prior art keywords
- methyl
- compound
- formula
- reacted
- hydrogen atom
- Prior art date
Links
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title claims description 4
- 238000000034 method Methods 0.000 title claims description 3
- 150000001556 benzimidazoles Chemical class 0.000 title description 3
- 238000002360 preparation method Methods 0.000 title description 3
- 230000001225 therapeutic effect Effects 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 239000002253 acid Substances 0.000 claims abstract description 3
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 claims abstract 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 18
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 6
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 4
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 claims description 4
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims description 2
- 150000002540 isothiocyanates Chemical class 0.000 claims 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 claims 1
- 229940116357 potassium thiocyanate Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 5
- 239000000739 antihistaminic agent Substances 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 239000000543 intermediate Substances 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 229910052736 halogen Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- LGDSHSYDSCRFAB-UHFFFAOYSA-N Methyl isothiocyanate Chemical compound CN=C=S LGDSHSYDSCRFAB-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- NGGXACLSAZXJGM-UHFFFAOYSA-N n-(diaminomethylidene)acetamide Chemical compound CC(=O)N=C(N)N NGGXACLSAZXJGM-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000003033 spasmogenic effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LDMXQNXCFMLIER-UHFFFAOYSA-N 1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]-n-methylpiperidin-4-amine Chemical compound C1CC(NC)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 LDMXQNXCFMLIER-UHFFFAOYSA-N 0.000 description 1
- LGNFDCKSSGEIIF-UHFFFAOYSA-N 1-[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-1,2-dimethylguanidine Chemical compound C1CC(N(C)C(=N)NC)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 LGNFDCKSSGEIIF-UHFFFAOYSA-N 0.000 description 1
- IBYWMGKTSAMYGX-UHFFFAOYSA-N 1-[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-1,3-dimethylthiourea Chemical compound C1CC(N(C)C(=S)NC)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 IBYWMGKTSAMYGX-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- QAWGALUNVIGMNL-UHFFFAOYSA-N N-[amino-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]methylidene]acetamide Chemical compound C1CC(N(C)C(N)=NC(C)=O)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 QAWGALUNVIGMNL-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- SMCJXKGCTZNQPP-UHFFFAOYSA-N acetic acid;1-[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-1-methylguanidine Chemical compound CC(O)=O.C1CC(N(C)C(N)=N)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 SMCJXKGCTZNQPP-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- -1 alkyl alkoxy acrylate Chemical compound 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001705 anti-serotonergic effect Effects 0.000 description 1
- ZXVOCOLRQJZVBW-UHFFFAOYSA-N azane;ethanol Chemical class N.CCO ZXVOCOLRQJZVBW-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 206010015907 eye allergy Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- LDKMUFDLRPXQQO-UHFFFAOYSA-N n-[[acetyl(methyl)amino]-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]methylidene]acetamide Chemical compound C1CC(N(C)C(=NC(C)=O)N(C)C(C)=O)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 LDKMUFDLRPXQQO-UHFFFAOYSA-N 0.000 description 1
- PVXDROSUPPQRKB-UHFFFAOYSA-N n-[n-[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-n,n'-dimethylcarbamimidoyl]acetamide Chemical compound C1CC(N(C)C(NC(C)=O)=NC)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVXDROSUPPQRKB-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Photoreceptors In Electrophotography (AREA)
- Liquid Developers In Electrophotography (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8710409A FR2618435B1 (fr) | 1987-07-23 | 1987-07-23 | Derives de benzimidazole, leur preparation et leur application en therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO883263D0 NO883263D0 (no) | 1988-07-22 |
| NO883263L true NO883263L (no) | 1989-01-24 |
Family
ID=9353449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO88883263A NO883263L (no) | 1987-07-23 | 1988-07-22 | Fremgangsmaate for fremstilling av terapeutisk aktive benzimidazol-derivater. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4857536A (de) |
| EP (1) | EP0304353B1 (de) |
| JP (1) | JP2690749B2 (de) |
| KR (1) | KR890002111A (de) |
| AT (1) | ATE94164T1 (de) |
| AU (1) | AU602418B2 (de) |
| CA (1) | CA1310010C (de) |
| DE (1) | DE3883891T2 (de) |
| DK (1) | DK413188A (de) |
| ES (1) | ES2059550T3 (de) |
| FI (1) | FI883484A (de) |
| FR (1) | FR2618435B1 (de) |
| HU (1) | HUT47266A (de) |
| IE (1) | IE61824B1 (de) |
| IL (1) | IL87174A (de) |
| NO (1) | NO883263L (de) |
| NZ (1) | NZ225528A (de) |
| PT (1) | PT88089B (de) |
| ZA (1) | ZA885367B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2658823B1 (fr) * | 1990-02-27 | 1992-04-30 | Adir | Nouveaux derives d'aminomethylpiperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent . |
| CA2097317C (en) * | 1990-12-14 | 2002-02-12 | Albert A. Carr | Antiallergic piperdinyl benzimidazoles |
| FR2674853B1 (fr) * | 1991-04-03 | 1995-01-20 | Synthelabo | Derives de piperidinylguanidine, leur preparation et leur application en therapeutique. |
| US5223704A (en) * | 1992-03-31 | 1993-06-29 | At&T Bell Laboratories | Planar buried quantum well photodetector |
| FR2693194B1 (fr) * | 1992-07-03 | 1994-09-23 | Synthelabo | Dérivés d'alcanecarboxamide, leur préparation et leur application thérapeutique. |
| FR2696176B1 (fr) * | 1992-09-28 | 1994-11-10 | Synthelabo | Dérivés de pipéridine, leur préparation et leur application en thérapeutique. |
| CN111417394B (zh) | 2017-10-19 | 2023-11-07 | 帝人制药株式会社 | 苯并咪唑衍生物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3528991A (en) * | 1964-02-19 | 1970-09-15 | Sterling Drug Inc | 1h- and 2h-benzotriazolyl-lower-alkyl-amidoximes,-amidines,and -guanidines |
| CA1140119A (en) * | 1978-04-03 | 1983-01-25 | Joseph Torremans | N-heterocyclyl-4-piperidinamines |
| US4347856A (en) * | 1980-05-20 | 1982-09-07 | United States Tobacco Company | Method and apparatus for removing cigar wrappers from the web of a bobbin |
| US4634704A (en) * | 1983-10-06 | 1987-01-06 | Janssen Pharmaceutica, N.V. | Anti-allergic five membered heterocyclic ring containing N-(bicyclic heterocycyl)-4-piperidinamines |
| FR2587029B1 (fr) * | 1985-09-11 | 1987-10-30 | Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
-
1987
- 1987-07-23 FR FR8710409A patent/FR2618435B1/fr not_active Expired
-
1988
- 1988-07-20 EP EP88401866A patent/EP0304353B1/de not_active Expired - Lifetime
- 1988-07-20 ES ES88401866T patent/ES2059550T3/es not_active Expired - Lifetime
- 1988-07-20 AT AT88401866T patent/ATE94164T1/de not_active IP Right Cessation
- 1988-07-20 DE DE88401866T patent/DE3883891T2/de not_active Expired - Fee Related
- 1988-07-21 IL IL87174A patent/IL87174A/xx not_active IP Right Cessation
- 1988-07-22 DK DK413188A patent/DK413188A/da not_active Application Discontinuation
- 1988-07-22 NO NO88883263A patent/NO883263L/no unknown
- 1988-07-22 ZA ZA885367A patent/ZA885367B/xx unknown
- 1988-07-22 FI FI883484A patent/FI883484A/fi not_active IP Right Cessation
- 1988-07-22 KR KR1019880009229A patent/KR890002111A/ko not_active Application Discontinuation
- 1988-07-22 AU AU19716/88A patent/AU602418B2/en not_active Ceased
- 1988-07-22 NZ NZ225528A patent/NZ225528A/xx unknown
- 1988-07-22 JP JP63184459A patent/JP2690749B2/ja not_active Expired - Fee Related
- 1988-07-22 HU HU883883A patent/HUT47266A/hu unknown
- 1988-07-22 PT PT88089A patent/PT88089B/pt not_active IP Right Cessation
- 1988-07-22 CA CA000572858A patent/CA1310010C/en not_active Expired - Lifetime
- 1988-07-22 US US07/222,758 patent/US4857536A/en not_active Expired - Lifetime
- 1988-07-22 IE IE225788A patent/IE61824B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IE882257L (en) | 1989-01-23 |
| DE3883891T2 (de) | 1994-04-14 |
| JPS6434978A (en) | 1989-02-06 |
| DK413188A (da) | 1989-01-24 |
| NO883263D0 (no) | 1988-07-22 |
| KR890002111A (ko) | 1989-04-08 |
| IL87174A0 (en) | 1988-12-30 |
| PT88089A (pt) | 1989-06-30 |
| EP0304353A1 (de) | 1989-02-22 |
| ES2059550T3 (es) | 1994-11-16 |
| JP2690749B2 (ja) | 1997-12-17 |
| EP0304353B1 (de) | 1993-09-08 |
| CA1310010C (en) | 1992-11-10 |
| AU1971688A (en) | 1989-01-27 |
| FR2618435B1 (fr) | 1989-10-27 |
| IE61824B1 (en) | 1994-11-30 |
| PT88089B (pt) | 1995-03-01 |
| DE3883891D1 (de) | 1993-10-14 |
| DK413188D0 (da) | 1988-07-22 |
| FR2618435A1 (fr) | 1989-01-27 |
| IL87174A (en) | 1993-02-21 |
| ATE94164T1 (de) | 1993-09-15 |
| NZ225528A (en) | 1990-05-28 |
| AU602418B2 (en) | 1990-10-11 |
| HUT47266A (en) | 1989-02-28 |
| ZA885367B (en) | 1989-06-28 |
| FI883484A (fi) | 1989-01-24 |
| US4857536A (en) | 1989-08-15 |
| FI883484A0 (fi) | 1988-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU820659A3 (ru) | Способ получени производных 4-амино- 5-АлКилСульфОНилОАНизАМидОВ, иХ СОлЕй,ОКиСЕй, лЕВО- и пРАВОВРАщАющиХизОМЕРОВ /иХ ВАРиАНТы/ | |
| FI88504B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 4-benzyl-1-(2h)-ftalazinonderivat | |
| JPS63132889A (ja) | キナゾリノン誘導体 | |
| SE430333B (sv) | Analogiforfarande for framstellning av n-alkylpiperidinderivat | |
| PT84896B (pt) | Processo para a preparacao de analogos de distamicina a com accao antineoplastica e anti-viral e de composicoes farmaceuticas que os contem | |
| JPH0220639B2 (de) | ||
| SE451015B (sv) | Substituerade moranolinderivat | |
| FI58494C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara n-(1'-bensylpyrrolidin-2'-ylmetyl)bensamider | |
| KR20190009377A (ko) | 티오펜 화합물 및 이의 합성 방법과 이의 의약에서의 용도 | |
| IE47884B1 (en) | Xanthine derivatives having antiallergic activity and pharmacological preparations containing them | |
| JPH037263A (ja) | アミノベンゼンスルホン酸誘導体 | |
| NO178968B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive aminopyrimidin-karboksamidderivater | |
| NO121950B (de) | ||
| Wuest et al. | Some Derivatives of 3-Pyridol with Parasympathomimetic Properties1 | |
| NO883263L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive benzimidazol-derivater. | |
| KR910009934B1 (ko) | 카르바모일-2-피롤리디논 화합물 | |
| HU195486B (en) | Process for preparing new pyridine derivatives | |
| RU2200737C2 (ru) | Пиримидо[4,5-b]индолы и промежуточное соединение (варианты) | |
| FI77028C (fi) | Analogifoerfarande foer framstaellning av terapeutiskt anvaendbart 4-(1-imidatzolylmetyl)kanelsyrahydroklorid- monohydrat. | |
| EP0039919B1 (de) | Benzoxazol und Benzothiazol-Derivate mit antiallergischer Wirkung | |
| EP1385858A1 (de) | Neue 5-thio-ss-d-xylopyranosidderivate, verfahren zu deren herstellung, diese enthaltende pharmazeutische zusammensetzungen und deren therapeutische verwendung | |
| EP0661273B1 (de) | Indan Derivate und Verfahren zu deren Herstellung | |
| CN115322077B (zh) | 一类烷基酚类化合物及其制备方法 | |
| Bagley et al. | Isomeric tropane analogues of histamine H2‐receptor antagonists | |
| JPS62212386A (ja) | ２−ピリジルメチルベンズイミダゾ−ル誘導体 |